Pharmicell Co Ltd

005690

Company Profile

  • Business description

    Pharmicell Co Ltd is a biotechnology company, engages in the manufacturing of biopharmaceutical medicines in South Korea. Its biopharmaceutical business engages in the development and manufacture of stem cell therapeutic drugs and stem cell-based cosmetics and others. Its products under development include mesenchymal stem cell products, such as Cellgram_AMI, a heart disease drug; Cellgram_IS and Cellgram_SCI, which are brain/nerve disorder drugs; Cellgram_Lung, a pulmonary disease drug; Cellgram_LC, a liver disease drug; and Cellgram_ED and Cellgram_CLI for the treatment of graft-versus-host disease, kidney transplant, impotence, and critical lower limb ischemia.

  • Contact

    12F Chungho B/D
    3-2 Nonhyun-dong Gangnam-gu
    Seoul135-010
    KOR

    T: +82 234960114

    http://www.pharmicell.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    31 December 2025

    Employees

    161

Stocks News & Analysis

stocks

Solid start to fiscal 2026 for BHP

Production guidance is maintained by management.
stocks

Coca-Cola earnings: Innovation and brand strength underpin growth

We plan to raise our fair value estimate of Coca-Cola stock.
stocks

Going into earnings, is Netflix stock a buy, a sell, or fairly valued?

Watching sales growth and the potential for margin expansion, here’s what we think of Netflix stock.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries9,321.1010.80-0.12%
CAC 408,229.4929.37-0.36%
DAX 4024,322.757.28-0.03%
Dow JONES (US)46,924.74218.160.47%
FTSE 1009,489.5362.540.66%
HKSE25,807.71219.84-0.84%
NASDAQ22,953.6736.88-0.16%
Nikkei 22549,307.798.27-0.02%
NZX 50 Index13,306.4471.41-0.53%
S&P 5006,735.350.220.00%
S&P/ASX 2009,030.0010.30-0.11%
SSE Composite Index3,913.762.57-0.07%

Market Movers